Crescendo is developing a pipeline of differentiated, next generation therapeutics with broad applicability across a range of key oncology indications with a focus on novel targeted T-cell activation.
Through both in-house development and strategic partnerships our oncology programmes aim to produce high value, differentiated therapeutics that capitalise on the many advantages of the Humabody® format. Humabody® therapeutics can be designed to use as stand-alone therapies or in combination, especially in the Immuno-Oncology field. At the heart of our proprietary pipeline, Crescendo has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment which it is rapidly advancing towards clinical development.
Crescendo also has additional Immuno-Oncology and Humabody® Drug Conjugate (HDC) assets which are available for partnering or out-license.
Our goal is to create novel Humabody® therapeutics capable of delivering safer more durable responses in a greater proportion of patients.